CardioDx to Assess Corus CAD as Part of PROMISE Study

CardioDx announced this week that it will use its Corus CAD molecular diagnostic to analyze samples from as many as 3,000 non-diabetic patients enrolled in a randomized trial comparing the efficacy of diagnostic strategies to gauge which stable patients suspected of having coronary artery disease actually have the condition.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.